Evidence map›Paper›PMID 33155752›Full record

ArticleAging cell2020

Alzheimer's amyloid β heterogeneous species differentially affect brain endothelial cell viability, blood-brain barrier integrity, and angiogenesis.

Rebecca Parodi-Rullán, Jorge Ghiso, Erwin Cabrera, Agueda Rostagno, Silvia Fossati

Open access · goldAbstract read
In one paragraph

Article in Aging cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Endothelial NADAlzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Amyloid β alters vascular CaThe Journal of physiology · 2025
    Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Rebecca Parodi-RullánAlzheimer's Center at Temple, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.ORCID 0000-0002-0466-1047
Jorge GhisoDepartment of Pathology, New York University School of Medicine, New York, NY, USA.
Erwin CabreraDepartment of Pathology, New York University School of Medicine, New York, NY, USA.
Agueda RostagnoDepartment of Pathology, New York University School of Medicine, New York, NY, USA.
Silvia FossatiAlzheimer's Center at Temple, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.ORCID 0000-0002-2047-222X
New York University · USTemple University · US

Funding

Relevance of Abeta N-terminal Truncations for Alzheimer Pathogenesis and Therapy - Resubmission - 1RF1AG059695 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GHISO, JORGE A · 2019 to 2019
$3.7M
Cerebral amyloid angiopathy, metabolic dysregulation, and the neurovascular unit - Resubmission - 1RF1AG065651 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GHISO, JORGE A · 2020 to 2020
$3.2M
Potentiation of CAA-mediated endothelial dysfunction by cardiovascular risk factorsR01NS104127 · NINDS · TEMPLE UNIV OF THE COMMONWEALTH · PI FOSSATI, SILVIA · 2018 to 2022
$3.0M
Targeting carbonic anhydrases in Alzheimer's diseaseR01AG062572 · NIA · TEMPLE UNIV OF THE COMMONWEALTH · PI FOSSATI, SILVIA · 2019 to 2023
$2.3M
CEREBROVASUCLAR AMYLOIDOSIS, STROKE, AND DEMENTIAR01NS051715 · NINDS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ROSTAGNO, AGUEDA · 2007 to 2011
$1.8M
NIA NIH HHS R01 AG062572NIA NIH HHS RF1 AG059695NIA NIH HHS RF1 AG065651NINDS NIH HHS R01 NS051715NINDS NIH HHS R01 NS104127
6 · The paper itself

Abstract

Impaired clearance in the Alzheimer's Disease (AD) brain is key in the formation of Aβ parenchymal plaques and cerebrovascular deposits known as cerebral amyloid angiopathy (CAA), present in >80% of AD patients and ~50% of non-AD elderly subjects. Aβ deposits are highly heterogeneous, containing multiple fragments mostly derived from catabolism of Aβ40/Aβ42, which exhibit dissimilar aggregation properties. Remarkably, the role of these physiologically relevant Aβ species in cerebrovascular injury and their impact in vascular pathology is unknown. We sought to understand how heterogeneous Aβ species affect cerebral endothelial health and assess whether their diverse effects are associated with the peptides aggregation propensities. We analyzed cerebral microvascular endothelial cell (CMEC) viability, blood-brain barrier (BBB) permeability, and angiogenesis, all relevant aspects of brain microvascular dysfunction. We found that Aβ peptides and fragments exerted differential effects on cerebrovascular pathology. Peptides forming mostly oligomeric structures induced CMEC apoptosis, whereas fibrillar aggregates increased BBB permeability without apoptotic effects. Interestingly, all Aβ species tested inhibited angiogenesis in vitro. These data link the biological effects of the heterogeneous Aβ peptides to their primary structure and aggregation, strongly suggesting that the composition of amyloid deposits influences clinical aspects of the AD vascular pathology. As the presence of predominant oligomeric structures in proximity of the vessel walls may lead to CMEC death and induction of microhemorrhages, fibrillar amyloid is likely responsible for increased BBB permeability and associated neurovascular dysfunction. These results have the potential to unveil more specific therapeutic targets and clarify the multifactorial nature of AD.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesBlood-Brain BarrierCell DifferentiationEndothelial CellsFemaleHumansMaleAmyloid beta-PeptidesAlzheimer's diseaseamyloid βangiogenesisblood-brain barriercerebral amyloid angiopathy

Identifiers

PMID33155752
PMCPMC7681048
OpenAlexW3096866785

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.